Strategic Partnership Enables Physicians to Conduct Clinical Research and Offer New Clinical Therapies to their Patients

AllscriptsAllscripts (NASDAQ:MDRX) has partnered with Elligo Health Research to assist clinicians to conduct clinical trial studies in their own clinics. Through the Allscripts / Elligo partnership, clinical trials managed by Clinical Research Organizations (CROs) will be available, bringing new treatments to patients across major therapeutic areas.

The combined offering enables physicians to directly participate as study investigators in selected CRO clinical trials, and delivers the physicians' patients the benefit of more direct comprehensive care. Additionally, physicians will be able to generate research revenue and cover investigator fees associated with trial procedures.

The Allscripts eParticipateSM service will be available to all Allscripts clients using the EHR platforms - Allscripts Professional EHRTM, Allscripts TouchWorks® EHR and Allscripts SunriseTM.

CROs continue to increase investments to support bringing new clinical therapies to market, with more than $17 billion in payments to study investigators. eParticipate expands the reach of clinical trials investments by enabling Allscripts research-capable sites to become study investigators through Elligo's infrastructure and services. Allscripts physicians will have access to clinical trials across several therapeutic areas, including Gastroenterology, Neurology, Pain, Urology, Pulmonology, Oncology and Women's Health, some of the key areas of focus for CROs.

"By bringing clinical trials directly to their patients, physicians can remain focused on the direct care of patients while offering them new therapies," said Allscripts Senior Vice President and General Manager of Payer and Life Sciences Jay Bhattacharyya. "Physicians will be able to participate in the benefits of clinical research without investing in expensive infrastructure."

"Through our partnership with Allscripts, health care providers can identify patients for potential clinical research opportunities directly through their EHR," said President of Elligo Health Research, Chad Moore. "Not only will patients gain access to treatments they might not have had otherwise, they will also participate from the comfort of their own physician's office."

About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of HealthTM. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations.

About Elligo Health Research
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes DirectTM with an approach that uses electronic health records and other health data to identify real-world physicians and patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician.

Most Popular Now

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

Brain Imaging may Identify Patients Like…

By understanding differences in how people’s brains are wired, clinicians may be able to predict who would benefit from a self-guided anxiety care app, according to a new analysis from...

Deep Learning-Based Model Enables Fast a…

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires accurate plaque and vessel wall segmentation and quantification for definitive diagnosis. However, conventional...

New AI Tool Illuminates "Dark Side…

Proteins sustain life as we know it, serving many important structural and functional roles throughout the body. But these large molecules have cast a long shadow over a smaller subclass...

The Human Touch of Doctors will Still be…

AI-based medicine will revolutionise care including for Alzheimer’s and diabetes, predicts a technology expert, but it must be accessible to all patients. Healing with Artificial Intelligence, written by technology expert Daniele...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...